FIELD: pharmacology.
SUBSTANCE: invention relates to application of a combination of a formula (III) compound with one or more additional drugs for the manufacture of a drug for use in therapy that inhibits the activity of anti-apoptotic Bcl-2 proteins. The radical values are set forth in claim p.1.
EFFECT: increased efficiency of compounds.
16 cl, 6 tbl, 19 ex
Title | Year | Author | Number |
---|---|---|---|
APOPTOSIS INDUCING AGENTS FOR TREATING MALIGNANT NEW GROWTH, AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535347C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATING MALIGNANT TUMOURS AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2573832C2 |
APOPTOSIS-INDUCING MEDICATIONS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2554346C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2014 |
|
RU2662812C2 |
APOPTOSIS-INDUCING PREPARATIONS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2009 |
|
RU2527450C2 |
APOPTOSIS INDUCING AGENTS SELECTIVE FOR Bcl-2 FOR CANCER AND IMMUNE DISEASES TREATMENT | 2013 |
|
RU2621052C2 |
BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR TREATING CANER AND IMMUNE DISEASES | 2010 |
|
RU2542994C2 |
BLC-2 SELECTIVE AGENTS CAUSING APOPTOSIS FOR TREATING CANCER AND IMMUNE DISEASES | 2009 |
|
RU2497822C2 |
SOLID DISPERSIONS CONTAINING AGENTS CAUSING APOPTOSIS | 2011 |
|
RU2598345C2 |
SOLID DISPERSIONS PRODUCED BY MELT EXTRUSION AND CONTAINING APOPTOSIS-INDUCING AGENT | 2011 |
|
RU2577859C2 |
Authors
Dates
2017-08-22—Published
2015-12-18—Filed